Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
76.06
+1.26 (1.68%)
At close: May 16, 2025, 4:00 PM
75.84
-0.22 (-0.29%)
After-hours: May 16, 2025, 7:59 PM EDT
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$852,293
Profits / Employee
$232,453
Market Cap
190.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| AbbVie | 55,000 |
MRK News
- 2 days ago - Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Business Wire
- 3 days ago - Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers - Business Wire
- 4 days ago - FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL) - Business Wire
- 4 days ago - Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 4 days ago - US FDA expands use of Merck's cancer drug for adrenal gland tumors - Reuters
- 4 days ago - Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. - Barrons
- 4 days ago - Germany's Merck drops China surcharge on orders after US-China tariff deal - Reuters
- 5 days ago - Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025 - Business Wire